COVID-19 and Cardiovascular Disease
- PMID: 32200663
- DOI: 10.1161/CIRCULATIONAHA.120.046941
COVID-19 and Cardiovascular Disease
Abstract
Coronavirus disease 2019 (COVID-19) is a global pandemic affecting 185 countries and >3 000 000 patients worldwide as of April 28, 2020. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2, which invades cells through the angiotensin-converting enzyme 2 receptor. Among patients with COVID-19, there is a high prevalence of cardiovascular disease, and >7% of patients experience myocardial injury from the infection (22% of critically ill patients). Although angiotensin-converting enzyme 2 serves as the portal for infection, the role of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers requires further investigation. COVID-19 poses a challenge for heart transplantation, affecting donor selection, immunosuppression, and posttransplant management. There are a number of promising therapies under active investigation to treat and prevent COVID-19.
Keywords: COVID-19; cardiovascular diseases; pandemics; severe acute respiratory syndrome coronavirus 2.
Similar articles
-
COVID-19 and the cardiovascular system.Nat Rev Cardiol. 2020 May;17(5):259-260. doi: 10.1038/s41569-020-0360-5. Nat Rev Cardiol. 2020. PMID: 32139904 Free PMC article.
-
Letter to the Editor: Angiotensin-converting enzyme 2: an ally or a Trojan horse? Implications to SARS-CoV-2-related cardiovascular complications.Am J Physiol Heart Circ Physiol. 2020 May 1;318(5):H1080-H1083. doi: 10.1152/ajpheart.00215.2020. Epub 2020 Mar 30. Am J Physiol Heart Circ Physiol. 2020. PMID: 32223552 Free PMC article. No abstract available.
-
Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?Pharmacol Res. 2020 Sep;159:104959. doi: 10.1016/j.phrs.2020.104959. Epub 2020 Jun 4. Pharmacol Res. 2020. PMID: 32505834 Free PMC article. No abstract available.
-
ACE2, the kidney and the emergence of COVID-19 two decades after ACE2 discovery.Clin Sci (Lond). 2020 Nov 13;134(21):2791-2805. doi: 10.1042/CS20200484. Clin Sci (Lond). 2020. PMID: 33135725 Review.
-
COVID-19: A Concern for Cardiovascular Disease Patients.Cardiovasc Toxicol. 2020 Oct;20(5):443-447. doi: 10.1007/s12012-020-09596-0. Epub 2020 Jul 29. Cardiovasc Toxicol. 2020. PMID: 32729064 Free PMC article. Review.
Cited by
-
Cardiac abnormalities due to multisystem inflammatory syndrome temporally associated with Covid-19 among children: A systematic review and meta-analysis.Int J Cardiol Heart Vasc. 2021 Apr;33:100764. doi: 10.1016/j.ijcha.2021.100764. Epub 2021 Mar 22. Int J Cardiol Heart Vasc. 2021. PMID: 33778151 Free PMC article. Review.
-
Key Strategies for Clinical Management and Improvement of Healthcare Services for Cardiovascular Disease and Diabetes Patients in the Coronavirus (COVID-19) Settings: Recommendations From the REPROGRAM Consortium.Front Cardiovasc Med. 2020 Jun 16;7:112. doi: 10.3389/fcvm.2020.00112. eCollection 2020. Front Cardiovasc Med. 2020. PMID: 32613010 Free PMC article.
-
How to overcome cardiovascular challenges in COVID-19 patients: a guide for common practice.Acta Biomed. 2020 Sep 7;91(3):e2020021. doi: 10.23750/abm.v91i3.9848. Acta Biomed. 2020. PMID: 32921718 Free PMC article. Review.
-
Influence of colchicine prescription in COVID-19-related hospital admissions: a survival analysis.Ther Adv Musculoskelet Dis. 2021 Mar 26;13:1759720X211002684. doi: 10.1177/1759720X211002684. eCollection 2021. Ther Adv Musculoskelet Dis. 2021. PMID: 33854571 Free PMC article.
-
Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies.Thromb Res. 2020 Dec;196:382-394. doi: 10.1016/j.thromres.2020.09.027. Epub 2020 Sep 24. Thromb Res. 2020. PMID: 32992075 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous